Thermo Fisher Scientific Inc. (NYSE:TMO) Shares Bought by MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH

MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH lifted its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 0.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,618 shares of the medical research company’s stock after acquiring an additional 88 shares during the period. MEAG MUNICH ERGO Kapitalanlagegesellschaft mbH’s holdings in Thermo Fisher Scientific were worth $13,067,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors also recently made changes to their positions in TMO. Phoenix Holdings Ltd. raised its holdings in shares of Thermo Fisher Scientific by 21.4% in the 3rd quarter. Phoenix Holdings Ltd. now owns 9,366 shares of the medical research company’s stock worth $4,750,000 after purchasing an additional 1,654 shares in the last quarter. DMC Group LLC raised its holdings in shares of Thermo Fisher Scientific by 16.5% in the 3rd quarter. DMC Group LLC now owns 592 shares of the medical research company’s stock worth $300,000 after purchasing an additional 84 shares in the last quarter. Montchanin Asset Management LLC raised its holdings in shares of Thermo Fisher Scientific by 1.1% in the 2nd quarter. Montchanin Asset Management LLC now owns 4,550 shares of the medical research company’s stock worth $2,374,000 after purchasing an additional 50 shares in the last quarter. Check Capital Management Inc. CA acquired a new stake in shares of Thermo Fisher Scientific during the third quarter valued at approximately $219,000. Finally, Tower Bridge Advisors raised its holdings in shares of Thermo Fisher Scientific by 0.5% during the third quarter. Tower Bridge Advisors now owns 33,046 shares of the medical research company’s stock valued at $16,727,000 after acquiring an additional 155 shares during the period. 89.23% of the stock is owned by institutional investors and hedge funds.

Thermo Fisher Scientific Stock Up 0.3 %

TMO stock traded up $1.84 during trading hours on Friday, hitting $581.21. The company’s stock had a trading volume of 1,081,545 shares, compared to its average volume of 1,473,417. The company has a quick ratio of 1.39, a current ratio of 1.75 and a debt-to-equity ratio of 0.67. The company has a market capitalization of $221.62 billion, a PE ratio of 37.62, a price-to-earnings-growth ratio of 2.43 and a beta of 0.80. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $603.82. The stock has a 50 day moving average price of $565.87 and a two-hundred day moving average price of $520.64.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, January 31st. The medical research company reported $5.67 EPS for the quarter, topping the consensus estimate of $5.64 by $0.03. The company had revenue of $10.89 billion during the quarter, compared to the consensus estimate of $10.73 billion. Thermo Fisher Scientific had a net margin of 13.99% and a return on equity of 18.78%. The company’s revenue for the quarter was down 4.9% compared to the same quarter last year. During the same period in the previous year, the firm posted $5.40 earnings per share. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 21.52 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Monday, April 15th. Investors of record on Friday, March 15th will be issued a dividend of $0.39 per share. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.35. This represents a $1.56 annualized dividend and a dividend yield of 0.27%. The ex-dividend date of this dividend is Thursday, March 14th. Thermo Fisher Scientific’s dividend payout ratio is currently 10.10%.

Insider Buying and Selling

In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, SVP Michael A. Boxer sold 14,566 shares of the company’s stock in a transaction on Wednesday, February 7th. The shares were sold at an average price of $562.00, for a total transaction of $8,186,092.00. Following the completion of the sale, the senior vice president now directly owns 12,901 shares of the company’s stock, valued at approximately $7,250,362. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, Director Debora L. Spar sold 164 shares of the company’s stock in a transaction on Monday, February 12th. The stock was sold at an average price of $546.97, for a total transaction of $89,703.08. Following the sale, the director now directly owns 1,207 shares of the company’s stock, valued at $660,192.79. The disclosure for this sale can be found here. In the last three months, insiders sold 50,277 shares of company stock valued at $28,513,384. Company insiders own 0.32% of the company’s stock.

Wall Street Analysts Forecast Growth

TMO has been the topic of a number of recent analyst reports. Robert W. Baird restated an “outperform” rating and set a $670.00 price target on shares of Thermo Fisher Scientific in a report on Thursday, December 14th. Royal Bank of Canada boosted their price target on shares of Thermo Fisher Scientific from $592.00 to $642.00 and gave the company an “outperform” rating in a report on Thursday, February 1st. Wolfe Research initiated coverage on shares of Thermo Fisher Scientific in a report on Wednesday, December 13th. They set an “outperform” rating and a $575.00 price target on the stock. Citigroup assumed coverage on shares of Thermo Fisher Scientific in a report on Monday, March 18th. They set a “neutral” rating and a $620.00 price target on the stock. Finally, TheStreet upgraded shares of Thermo Fisher Scientific from a “c+” rating to a “b-” rating in a research note on Friday, December 22nd. Five research analysts have rated the stock with a hold rating and eleven have given a buy rating to the stock. According to data from MarketBeat, Thermo Fisher Scientific presently has an average rating of “Moderate Buy” and an average target price of $599.00.

Thermo Fisher Scientific Company Profile

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.